Key Points:
- Exact Sciences, a leading provider of cancer screening and diagnostic tests, has launched an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients.
- This initiative is aimed at advancing precision cancer medicine by enhancing the collection of data accessible to Mayo Clinic researchers and clinicians, thereby advancing cancer research and patient care.
- Kevin Conroy, chairman and CEO of Exact Sciences, emphasized that the collaboration aims to eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment.
- Specialists at the center care for over 130,000 unique cancer patients each year across three sites in the United States. Access to Exact Sciences’ tests will guide therapeutic decisions and support the development of new diagnostic tests and therapies.
- The OncoExTra® test, a comprehensive DNA and RNA-based genomic test, provides a detailed molecular picture of a patient’s cancer. The Riskguard™ hereditary cancer test helps understand a patient’s hereditary risk of cancer.